Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05985551 | Delayed SLND for Patients With Breast Cancer Undergoing Primary Systemic Treatment(MagNeo) | active not recruiting | — | 114 | Uppsala UniversityOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT03982485 | Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer(APP) | active not recruiting | Phase 2 | 196 | RenJi HospitalOTHER | 1 | Apr 30, 2024 |
| clinicaltrials |
| NCT05257577 | Factors Influencing Breast Cancer Resection Volumes And Their Impact on Treatment Outcome (FIBRATIO)(FIBRATIO) | active not recruiting | — | 220 | Tampere University HospitalOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT05931445 | Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer | active not recruiting | N/A | 500 | Comprehensive Support Project for Oncology ResearchOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT02240836 | Energy Balance and Breast Cancer Aspects-II(EBBA-II) | active not recruiting | N/A | 545 | Oslo University HospitalOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03281954 | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo | active not recruiting | Phase 3 | 1,550 | NSABP Foundation IncNETWORK | 2 | Apr 8, 2024 | clinicaltrials |
| NCT01996267 | Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2(TRAIN-2) | active not recruiting | Phase 3 | 437 | The Netherlands Cancer InstituteOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT02474641 | Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer(HYPOSIB) | active not recruiting | N/A | 2,324 | University Hospital Schleswig-HolsteinOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT03595592 | Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer(APTneo) | active not recruiting | Phase 3 | 650 | Fondazione MichelangeloOTHER | 4 | Mar 6, 2024 | clinicaltrials |
| NCT05441943 | Lymphaticovenous Anastomosis as Treatment for Lymphedema | active not recruiting | N/A | 10 | Odense University HospitalOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT05698056 | A Retrospective Analysis of Magnetic Resonance Imaging Data for Breast Cancer Screening in the Open Consortium for Decentralized Medical Artificial Intelligence(ODELIA) | active not recruiting | — | 25,000 | Technische Universität DresdenOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02641847 | TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature | active not recruiting | Phase 2 / Phase 3 | 503 | Fudan UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT02965950 | The p53 Breast Cancer Trial(p53b) | active not recruiting | Phase 2 | 190 | Haukeland University HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT01717131 | Axillary Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node | active not recruiting | N/A | 2,228 | Institut Paoli-CalmettesOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT05132790 | Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment | active not recruiting | N/A | 24 | Shengjing HospitalOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT01872975 | Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery | active not recruiting | N/A | 1,636 | NSABP Foundation IncNETWORK | 7 | Dec 27, 2023 | clinicaltrials |
| NCT03561454 | A Registry of Intra-Operative Radiation Therapy (IORT) Using the Xoft ® Axxent ® eBx ™ System Patients | active not recruiting | — | 100 | MedStar Franklin Square Medical CenterOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT04172259 | ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC | active not recruiting | Phase 2 | 156 | Sun Yat-sen UniversityOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT03324932 | Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer | active not recruiting | Phase 3 | 160 | Kyoto Prefectural University of MedicineOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05569811 | NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial(VALENTINE) | active not recruiting | Phase 2 | 120 | SOLTI Breast Cancer Research GroupOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT00909909 | Radiation Therapy in Treating Women With Early Stage Breast Cancer | active not recruiting | Phase 2 | 200 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05955521 | Exosome as the Prognostic and Predictive Biomarker in EBC Patients | active not recruiting | N/A | 200 | Samsung Medical CenterOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05824325 | Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer(GALAXY) | active not recruiting | Phase 1 / Phase 2 | 56 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT04642508 | The PreQ-20 TRIAL, a Prospective Cohort Study of Patients Undergoing Prepectoral Breast Reconstruction(PreQ-20) | active not recruiting | N/A | 81 | University Hospital A CoruñaOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT02889458 | Hong Kong Breast Cancer Study | active not recruiting | — | 7,000 | The University of Hong KongOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT02315196 | Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | active not recruiting | Phase 2 | 62 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT02400658 | Efficacy of IORT With CT-Guided HDR Brachytherapy for Treatment of Breast Cancer | active not recruiting | N/A | 358 | Shayna Showalter, MDOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT02261389 | Follow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET | active not recruiting | N/A | 1,507 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT01057069 | Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer(neo-TN) | active not recruiting | Phase 2 / Phase 3 | 310 | The Netherlands Cancer InstituteOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT01646034 | High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer(Oligo) | active not recruiting | Phase 3 | 74 | The Netherlands Cancer InstituteOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04486911 | Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial | active not recruiting | Phase 2 | 89 | Shengjing HospitalOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT02339779 | Breast Reconstruction With External Pre-expansion and Autologous Fat Transfer Versus Standard Therapy(BREAST) | active not recruiting | N/A | 196 | Maastricht University Medical CenterOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT02603679 | Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases(PREDIX LumB) | active not recruiting | Phase 2 | 181 | Thomas HatschekOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT02568839 | Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer(PREDIX HER2) | active not recruiting | Phase 2 / Phase 3 | 202 | Thomas HatschekOTHER | 1 | Aug 13, 2020 | clinicaltrials |
| NCT02592083 | Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors(PREDIX LumA) | active not recruiting | Phase 2 | 10 | Thomas HatschekOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02338310 | Trial of Perioperative Endocrine Therapy - Individualising Care(POETIC) | active not recruiting | Phase 3 | 4,486 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02491697 | Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer | active not recruiting | Phase 2 | 400 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
Data updated 22 days agoSource updated May 3, 2024source: clinicaltrials